The FDA approved DAB389IL2, known as denileukin diftitox (Ontak®), as the first IT. After that, numerous preclinical and clinical studies were conducted to identify a potential IT that could be used in monotherapy or in combination with other agents (Allahyari et al., 2017; Frankel...
“Acute Market Reports Logo” Commercial Avionics Market (By System Type– Flight Control and Management Systems, Display Suites, Radio Tuning and Communication Systems, In-flight Entertainment Systems; By Channel: Forward Fit and Retrofit; By Aircraft Type: Fixed Wing and...
“Acute Market Reports Logo” The global power tools market is expected to expand at a CAGR of 5.2% from 2017 to 2025, reaching US$ 45.2 Bn by 2025. Global Power Tools Market (By End-use Application (Non-residential (Construction and Mining, A...
1 Sarcopenia is a chronic, progressive muscle disease characterized by a loss of intrinsic physical capacity that is seen with aging and numerous acute and chronic conditions.2-6 Originally defined as the loss of skeletal muscle mass associated with reduced strength and physical function seen with ...
Paczulla, A. M. et al. Long-term observation reveals high-frequency engraftment of human acute myeloid leukemia in immunodeficient mice. Haematologica 102, 854–864 (2017). Article CAS PubMed PubMed Central Google Scholar Harris, P. A. et al. Research electronic data capture (REDCap)—a...
However, Mylotarg® was re-approved in 2017 for newly diagnosed CD33-positive AML (acute myeloid leukemia), with lower recommended dose levels and an altered dosing regimen featuring dose fractionation (Baron & Wang, 2018). The field of ADCs is still expanding with a significant increase ...
“success of treatment” encompassed patients receiving 6 cycles, being alive 180 days after end of trial treatment without progressive disease, unacceptable toxicity, acute graft-versus-host-disease (GvHD) of grade-3 or higher, or extensive chronic GvHD. A total of 70 patients were screened, ...
20170121420 ANTI-IL1RAP ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND IL1RAP AND CD3, AND USES THEREOF 2017-05-04 Heidrich et al. 9458237 Method for inducing cell death in acute lymphoblastic leukemic system cells 2016-10-04 Fioretos et al. 9403906 Method of treatment of a solid...
Journal2017,European Journal of Cancer Wolfram C.M.Dempke, ...Stephen P.Dale 4Co-stimulatory targets 4.14-1BB (CD137) The 4-1BBprotein receptor(CD137)CD137(4-1BB) is asurfaceglycoproteinthat belongs to thetumour necrosis factor receptorsuperfamily[28]. CD137 is an inducible co-stimulatory...
2017III713NSCLC1. CRT 2. CRT + IO1° + inv LN2 Gy x 30DurvaRT→ IOPFS 5.6 vs 16.8m (P<0.001) 2y OS 56 vs 66% (P=0.005) NCT02743494 CHECK MATE 577Kelly NEJM 2021III794Esophag-eal1. CRT + surg 2. CRT + surg + IO1° + inv LN1.8 Gy x 23-28NivoRT→ IODFS 11 vs 22....